Thankful to everyone Barts Health @WhippsCrossHosp for making this happen so quickly and efficiently. Feeling extremely fortunate with a touch of hope ✨

Ten days at the Royal London Hospital. Our reporting from the frontline of the war on coronavirus. All this week ⁦BBC One⁩ bbcnewssix #bbcnewsten.

Hands on experience and training on the care of an intensive care patient today @BartsHospital Brilliant course run by @sim_stbarts at a time when many are new to the ITU environment. Can’t recommend it enough.

I’m as proud of this as anything I’ve ever written. Launched today for Greater Manchester Cancer Alliance #WorldCancerDay . Mancunian or not, if you or yours have ever been affected by cancer then do please take a few minutes to watch and share. Video link below. #InnitLove

CT scan catches 70% of lung cancers at early stage, NHS study finds | Lung cancer | The Guardian theguardian.com/society/2021/f…

Ever felt lost in an MDT ? 🙋🏼‍♀️ Ever wondered how to get educational value from an MDT? 🙋🏼‍♀️ Then look at this 👇🏼👇🏼👇🏼 🚨NEW “MDT Meetings Training Day” running @BartsHospital A half day course all about maximising your MDT Experience ✨ Will Ricketts 💙 🕊️ @sim_stbarts @maxi_beth

We have 2 spaces for #nurses working in #acutewards #emergencymedicine #oncology Barts Health DM me if more details needed or see booking details BartsHealth Sim

A fantastic opportunity for those interested in gaining experience in oncology whilst also working in an excellent education and simulation department! 🧩🩺🧬

Brilliant day delivering the new Acute Oncology study day with @sim_stbarts Barts Cancer Team. Great to see how simulation can be used so effectively to deliver and improve education in oncology 🧩🧬

Fantastic piece of work by Nicola Smallcombe & @maxi_beth two of our Barts Health Education Academy Fellows presented at #ERSCongress #ERS2021. I really worry about how the next generation of Drs learn about #MDT working? Has the pandemic helped or hindered? #RespIsBest 🫁

Brilliant time at my first Association of Cancer Physicians trainee weekend. Very thankful we can all be there in person..hopefully many more to come! #ACP21

Also some great work led by some of our Trainees Alfred So & @maxi_beth attending their first BTOG hopefully they’re hooked #RespIsBest 🫁

Dr Elizabeth Nally Beth Nally from Barts Experimental Cancer Medicine Centre presents at #GU25 QoL tools and toxicity definitions require re-evaluation in the IO era. She validates novel tools within PRISM, a ph2 RCT. Response to Tx appears to influence QoL more than any other parameter, incl life changing tox

Biomakers in RCC have been disappointing. RNA immune & angio signatures were identified in Immotion150 Brian Rini, MD Cabozantinib + Nivolumab in RNA Cluster 1/2 (angio) in M1 RCC shows great response rates in these patients. We can do these difficult studies #ESMO25 OncoAlert

Excited to be at my first ESMO in wonderful Berlin! #ESMO25

1/2 KN905 Enfortumab Vedotin + Pembro continues to transform bladder cancer in spectacle fashion. In cisplatin ineligible operable disease it beats cystectomy with EFS HR 0.4, OS HR 0.5. pCR of 57% is much ⬆️ than anything before #ESMO25 pCR> 50% questions unselected surgery

Incredibly exciting data in perioperative #BladderCancer yesterday at #ESMO25 NAj EV-Pem 57% pCR in the cis-ineligible population. Can’t wait to see what’s next with the upcoming randomized ph3 #KeynoteB15 🔬 Might we be able to avoid cystectomy in these patients?

IMvigor011 marks a major step forward for perioperative cancer care. Using ctDNA to identify who truly benefits from adjuvant therapy spares others unnecessary and potentially life long toxicity, improves quality of life and reduces healthcare burden.

First ph3 RCT showing PFS benefit with adjuvant combination therapy in RCC! Growing evidence to support periop therapy following host of negative studies. Work to be done in identifying those most likely to benefit from therapy

Randomized trials testing ctDNA and HER-2 biomarkers in bladder cancer both delivered positive results with OS #ESMO25 . Here Sara Coca Membribes described how these and other biomarkers are changing bladder cancer. Petros Grivas OncoAlert #uromigosLive